Dengue Fever Pipeline Set for Significant Expansion by 2026 with 10+ Emerging Therapies and Strategic Advancements from Merck, Novartis, Johnson & Johnson, and Panacea Biotec | DelveInsight

AI Briefing

• – Dengue fever pipeline set for significant expansion by 2026 with emerging therapies from Merck, Novartis, Johnson & Janssen, and Panacea Biotec, driving transformation in the therapeutic landscape.
• – Increased global disease burden and rising research investments are driving the growth of the dengue fever pipeline, with multiple innovative candidates in various stages of development.
• – Strategic advancements in vaccine and therapeutic technologies, including mRNA-based vaccines and monoclonal antibodies, are expected to transform the treatment and prevention of dengue fever in the coming years.